Several pharma companies think that targeting a rogue protein known as alpha-synuclein could be the key to halting or reversing neurodegeneration in Parkinson’s disease – but has the industry learned from a string of failures in Alzheimer’s? In the space of a few weeks, Novartis AG and Sanofi AS have signed major deals for molecules targeting misfolded alpha-synuclein, the rogue protein thought to be the root cause of Parkinson’s disease
Big pharma puts bets on alpha-synuclein i... - Cure Parkinson's
Big pharma puts bets on alpha-synuclein in Parkinson’s – but will they pay off?
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Is there any evidence that alpha-synuclein is the culprit rather than an innocent side effect?
Not what you're looking for?
You may also like...
LL-37, a natural antimicrobial molecule present in the brain and gut, Suppresses Alpha-synuclein Clumping in Parkinson’s
"LL-37, a natural antimicrobial molecule present in the brain and gut, selectively binds to harmful...
Copper Leads to Protein Aggregation in Parkinson’s Disease
@[213807] found this! Copper Leads to Protein Aggregation in Parkinson’s Disease July 7 2022...
Is Parkinson’s Disease a Prion Disease? Alpha synuclein and prion-like behavior.
Prion diseases are a type of infectious disease transmitted by a self-replicating protein, the...
More Reason for Cautious Optimism
“The concept is that aggregates of the protein alpha-synuclein, thought to play a key role in the...
Feedback from a PD research scientist in the department of Clinical Neuroscience at the University of Cambridge (UK), on PASADENA Trial...
I am interested in participating in the best clinical trial I can get in to and specifically those...